These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Successful treatment of Kaposiform hemangioendothelioma with everolimus.
    Author: Uno T, Ito S, Nakazawa A, Miyazaki O, Mori T, Terashima K.
    Journal: Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933.
    Abstract:
    There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine. We described an eight-year-old male with KHE in the right femur that was resistant to prednisolone, vincristine and propranolol. Everolimus, an inhibitor of mammalian target of rapamycin (mTOR) at the dosage of 0.1 mg/kg/day, successfully decreased the tumor size and controlled the symptoms. Everolimus should be further studied as an alternative agent to sirolimus in the management of KHE.
    [Abstract] [Full Text] [Related] [New Search]